Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index

Clinical efficacy is the basis of traditional Chinese medicine development, and scientific evaluation of TCM clinical efficacy and its effectiveness is the way to push TCM modernized and international. TCM theories of Overall concept and Differentiation for life science and diseases are hard to be generally accepted. Besides, no unified and standard methods fit to evaluate the TCM clinical efficacy. Thus, there is a need to do a deeper research of methodology, evaluative index, and evaluative criteria in order to guide the evaluation of TCM clinical efficacy.

Based on the situation above, the study aims to choose the best and characteristic evaluative index of clinical efficacy, compare the demand among practitioners, patients and care givers. After data collected, a new cluster of index among Biochemical, patients report outcomes, endpoint indicators, and TCM soft indicators could be constituted and analyzed to use in respective way according to their characteristics, target and function.

Inclusion criterion：

• The diagnosis standard according with stable angina coronary heart disease
• The participants with any one of the below six standards are included:

• history of myocardial infarction previously
• PCI postoperative patients
• CT showing more than 50% coronary stenosis
• Coronary angiography showing more than 50% coronary stenosis
• positive results of the electrocardiogram
• ischemia changes in the electrocardiogram recently
• The Patients with disease history more than three months, attacked in the recent one month
• Standard according to the phlegm and blood stasis syndrome or Qi deficiency and blood stasis syndrome of the traditional Chinese medicine
• Male: 45 years old < 75 years old
• Female: 50 years old < 75 years old
• Participants signed the agreement paper voluntarily.

Exclusion criterion:

• Participants with Acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina), asymptomatic myocardial ischemia,ischemic cardiomyopathy,the myocardial infarction happening in the 3 months before the test
• Participants with rheumatism heart disease, hyper thyroid heart disease, hypertensive heart disease, myocarditis, cardiomyopathy
• Participants with Cervical disease, gallbladder cardiac syndrome, stomach and esophageal reflux, aortic dissection
• Participants with acute cerebral infarction and cerebral hemorrhage
• Participants with severe heart failure, lung function, liver function (AST, ALT 1.5 times normal standard), kidney function (BUN, Cr more than the normal standard), hematopoietic system and endocrine systems and serious primary disease, malignant tumor, gastrointestinal bleeding, gastric ulcer and are prone to bleed
• the Participants can not complete the whole test
• The serious high blood pressure and hard to control (SBP >= 180 mmHg or DBP >=110 mmHg)
• Participants of acute or chronic cardiac dysfunction with heart function III-IV
• Participants has been included in other clinical studies in one month;
• Participants with glaucoma
• Participants with Pregnancy Or Lactation ,Allergy
• Participants with mental disorder, or nervous disease, or illiteracy, or bad compliance for questionnaire